tetano
Editor, Senior Moderator
Aging (Albany NY)
. 2021 Mar 19;13.
doi: 10.18632/aging.202742. Online ahead of print.
Fungal co-infection in COVID-19 patients: evidence from a systematic review and meta-analysis
Jingwen Peng[SUP] 1 2 [/SUP], Qiong Wang[SUP] 1 2 [/SUP], Huan Mei[SUP] 1 2 [/SUP], Hailin Zheng[SUP] 1 2 [/SUP], Guangzhao Liang[SUP] 1 2 [/SUP], Xiaodong She[SUP] 1 2 [/SUP], Weida Liu[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) has infected tens of millions of people worldwide within the last year. However, the incidence of fungal co-infection in COVID-19 patients remains unclear. To investigate the association between fungal co-infection and mortality due to COVID-19, we systematically searched Medline, Embase, MedRxiv and Cochrane Library for eligible studies published in the period from 1 January to 1 December 2020. We performed a meta-analysis of nine studies that met the inclusion criteria. In total, data from 2780 patients and 426 patients were included who were admitted to the ICU. In eight of the articles, 211 participants died due to COVID-19 infection, which means an overall mortality rate of 10.9%. The overall pooled proportion of fungal co-infection in COVID-19 patients was 0.12 (95% CI = 0.07-0.16, n = 2780, I[SUP]2[/SUP] = 96.8%). In terms of mortality in COVID-19 patients with fungal infection, the overall pooled proportion of mortality was 0.17 (95% CI = 0.10-0.24, n = 1944, I[SUP]2[/SUP] = 95.6%). These findings provide evidence suggesting a favorable use for empirical antibiotics in the majority of patients when COVID-19 infection is diagnosed. Our analysis is investigating the use of antifungal therapy to treat COVID-19 can serve as a comprehensive reference for COVID-19 treatment.
Keywords: COVID-19; fungal co-infection; meta-analysis; systematic review.
. 2021 Mar 19;13.
doi: 10.18632/aging.202742. Online ahead of print.
Fungal co-infection in COVID-19 patients: evidence from a systematic review and meta-analysis
Jingwen Peng[SUP] 1 2 [/SUP], Qiong Wang[SUP] 1 2 [/SUP], Huan Mei[SUP] 1 2 [/SUP], Hailin Zheng[SUP] 1 2 [/SUP], Guangzhao Liang[SUP] 1 2 [/SUP], Xiaodong She[SUP] 1 2 [/SUP], Weida Liu[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 33744863
- DOI: 10.18632/aging.202742
Abstract
Coronavirus disease 2019 (COVID-19) has infected tens of millions of people worldwide within the last year. However, the incidence of fungal co-infection in COVID-19 patients remains unclear. To investigate the association between fungal co-infection and mortality due to COVID-19, we systematically searched Medline, Embase, MedRxiv and Cochrane Library for eligible studies published in the period from 1 January to 1 December 2020. We performed a meta-analysis of nine studies that met the inclusion criteria. In total, data from 2780 patients and 426 patients were included who were admitted to the ICU. In eight of the articles, 211 participants died due to COVID-19 infection, which means an overall mortality rate of 10.9%. The overall pooled proportion of fungal co-infection in COVID-19 patients was 0.12 (95% CI = 0.07-0.16, n = 2780, I[SUP]2[/SUP] = 96.8%). In terms of mortality in COVID-19 patients with fungal infection, the overall pooled proportion of mortality was 0.17 (95% CI = 0.10-0.24, n = 1944, I[SUP]2[/SUP] = 95.6%). These findings provide evidence suggesting a favorable use for empirical antibiotics in the majority of patients when COVID-19 infection is diagnosed. Our analysis is investigating the use of antifungal therapy to treat COVID-19 can serve as a comprehensive reference for COVID-19 treatment.
Keywords: COVID-19; fungal co-infection; meta-analysis; systematic review.